Companies sponsors |
Roche (mosunetuzumab) |
Others |
Department of Health and Social Care |
|
NHS England |
|
Welsh Government |
Patient carer groups |
Blood Cancer UK |
|
Leukaemia Care |
|
Lymphoma Action |
Professional groups |
Association of Cancer Physicians |
|
Cancer Research UK |
|
Royal College of Physicians |
|
Royal College of Radiologists |
Associated public health groups |
None |
Comparator companies |
Bristol Myers Squibb (lenalidomide) (confidentiality agreement signed, participating) |
|
Accord Healthcare (bendamustine) (confidentiality agreement not signed, not participating) |
|
Dr Reddy’s Laboratories (bendamustine) (confidentiality agreement not signed, not participating) |
|
Napp Pharmaceuticals (rituximab) (confidentiality agreement not signed, not participating) |
|
Pfizer (rituximab) (confidentiality agreement not signed, not participating) |
|
Roche (obinutuzumab, rituximab) (confidentiality agreement not signed, not participating) |
|
Sandoz (rituximab) (confidentiality agreement not signed, not participating) |
|
Seacross Pharmaceuticals (bendamustine) (confidentiality agreement not signed, not participating) |
|
Zentiva (bendamustine) (confidentiality agreement not signed, not participating) |
General commentators |
All Wales Therapeutics & Toxicology Centre |
|
British National Formulary |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
Scottish Medicines Consortium |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
Institute of Cancer Research |